The amount of weight you can realistically lose with tirzepatide varies depending on factors like your starting weight, dosage, adherence to treatment, and lifestyle habits
In its brief opposing the preliminary injunction, the FDA defends its data-driven conclusion that "Lilly's supply is currently exceeding demand and will meet or exceed projected demand across all strengths of Mounjaro and Zepbound." The FDA's determination relied heavily on confidential data provided by Lilly
Sango K, Takaku S, Tsukamoto M, Niimi N, Yako H
He said GLP-1 receptor agonists and substance use outcomes cannot shape formal treatment protocols until that evidence exists
This could indicate a systemic drug reaction
Abstract Purpose of Review This review summarizes recent advances in the clinical applications of glucagon-like peptide-1 receptor agonists (GLP-1RAs) beyond their established role in glycemic control for type 2 diabetes (T2DM)